Clinical-serological phenotypes map to distinct pulmonary patterns and outcomes in Sjögren disease-associated interstitial lung disease: a multicentre cluster analysis from the ISLAND and GRISS Study Groups of the Italian Society of Rheumatology
Background Sjögren disease-associated interstitial lung disease (SjD-ILD) is heterogeneous in pulmonary morphology and clinical course. We investigated whether clinical-serological phenotypes of SjD were associated with distinct pulmonary expressions and outcomes. Methods This retrospective multicentre study included patients with primary SjD and HRCT-confirmed ILD from 13 Italian centres within the ISLAND and GRISS networks. Unsupervised TwoStep clustering used five prespecified variables selected a priori on clinical and biological grounds to capture key dimensions of the disease: age at SjD diagnosis, triple anti-Ro60/Ro52/La positivity, rheumatoid factor positivity, hypergammaglobulinaemia and recurrent salivary gland swelling. Pulmonary variables, treatment and outcomes were excluded from clustering and analysed as external correlates. Clinically significant ILD deterioration was defined as absolute FVC decline ≥10 percentage points and/or new requirement for long-term oxygen therapy, lung transplantation or ILD-related death. Results Among 140 patients, mean ILD follow-up was 4.9 years. Clustering included 133 patients and identified two balanced clinical-serological phenotypes. Cluster 1 (n=67) was characterised by older age at SjD diagnosis (67.6 vs 57.4 years; p<0.001) and less prominent conventional B-cell-related features. Cluster 2 (n=66) showed enrichment in hypergammaglobulinaemia (81.8% vs 0%; p<0.001), triple anti-Ro60/Ro52/La positivity (50.0% vs 0%; p<0.001), low C4 (22.7% vs 3.0%; p<0.001), lymphadenopathy (27.3% vs 9.0%; p=0.006), haematological involvement (25.8% vs 4.5%; p<0.001) and lymphopenia (21.5% vs 9.1%; p=0.048). ILD was diagnosed before or within 3 months of SjD diagnosis more often in Cluster 1 (73.1% vs 43.9%; p<0.001), with greater smoking exposure (48.4% vs 25.0%; p=0.006) and more frequent UIP (25.4% vs 11.5%; p=0.046), whereas LIP was enriched in Cluster 2 (32.8% vs 6.8%; p<0.001). Clinically significant ILD deterioration was assessable in 110 patients and more frequent in Cluster 1 (49.1% vs 26.9%; p=0.020), as were hard ILD-related endpoints (20.9% vs 7.6%; p=0.028). UIP remained independently associated with deterioration (OR 6.29, 95% CI 1.68–23.56; p=0.006), while the cluster association was attenuated after adjustment for pulmonary morphology and clinical covariates. Conclusions Clinical-serological phenotypes of SjD were associated with distinct pulmonary expressions and outcomes in SjD-ILD. Integrating SjD phenotyping with pulmonary characteristics may improve patient stratification and inform future biological and treatment-response studies.
Authors
- Gaetano La Rocca (ORCID: https://orcid.org/0000-0002-1808-7090)
- Marta Favero (ORCID: https://orcid.org/0000-0002-1079-6669)
- Cecilia Burattini (ORCID: https://orcid.org/0009-0009-5635-0492)
- Raffaele Barile (ORCID: https://orcid.org/0009-0000-1081-7928)
- Lorenzo Dagna (ORCID: https://orcid.org/0000-0002-7428-315X)
- Andrea Faggiano (ORCID: https://orcid.org/0000-0002-3247-3203)
- Annalisa Marino (ORCID: https://orcid.org/0000-0002-2511-7374)
- Elena Bartoloni (ORCID: https://orcid.org/0000-0003-4776-2136)
- Eneida Cela
- Francesca Ruffilli (ORCID: https://orcid.org/0000-0001-5437-3935)
- Serena Guiducci
- Laura Cometi (ORCID: https://orcid.org/0000-0002-7710-5025)
- Angelo Fassio (ORCID: https://orcid.org/0000-0001-9187-232X)
- Cinzia Rotondo (ORCID: https://orcid.org/0000-0003-1356-8423)
- Chiara Baldini (ORCID: https://orcid.org/0000-0002-4454-1824)
- Paola Conigliaro (ORCID: https://orcid.org/0000-0001-7905-8413)
- Addolorata Corrado (ORCID: https://orcid.org/0000-0001-6823-1970)
- Onorina Berardicurti (ORCID: https://orcid.org/0000-0002-2808-1581)
- Francesco Ferro (ORCID: https://orcid.org/0000-0003-2834-9768)
- Martina Nicchi
- Francesca Cozzini (ORCID: https://orcid.org/0009-0007-8940-1634)
- Marco Sebastiani (ORCID: https://orcid.org/0000-0002-1294-6421)
- Filippo Santoro
- Eugenio Capparelli (ORCID: https://orcid.org/0009-0008-0208-4259)
- Paola Faggioli
- Marta di Berardino (ORCID: https://orcid.org/0009-0005-2104-6731)
- Andrea Lo Monaco
- Gabriele Gallina
- Gemma Lepri
- Andreina Manfredi
- Marta Mosca
Institutions
- University of Foggia (IT)
- University of Pisa (IT)
- University of Rome Tor Vergata (IT)
- University of Verona (IT)
- University of Modena and Reggio Emilia (IT)
- University of Parma (IT)
- Vita-Salute San Raffaele University (IT)
- University of Ferrara (IT)
- University of L'Aquila (IT)
- University of Perugia (IT)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- AULSS 2 Marca Trevigiana (IT)
- Azienda Unità Sanitaria Locale Piacenza (IT)
- Arcispedale Sant'Anna (IT)
- IRCCS Ospedale San Raffaele (IT)
- Guglielmo da Saliceto Hospital (IT)
- Campus Bio Medico University Hospital (IT)
- Ca' Foncello Hospital (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Link Campus University (IT)
- Aziende Socio Sanitarie Territoriale Ovest Milanese (IT)
- University of Florence (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fimmu.2026.1998253
- Primary Topic
- Salivary Gland Disorders and Functions
- Type
- article
- Field-Weighted Citation Impact
- 0.00